Flibanserin for the Treatment of Urinary Incontinence and Related Diseases

Abstract

The invention relates to the use of Flibanserin for the treatment or prevention of urinary incontinence and related diseases. In a further embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment or prevention of urinary incontinence and related diseases.

1 . A method for treating or preventing urinary incontinence comprising administering a therapeutically effective amount of Flibanserin 1, or a pharmacologically acceptable acid addition salt, hydrate, or solvate thereof. 
     
     
         2 . The method for treating or preventing urinary incontinence according to  claim 1 , further comprising administering and an active ingredient 2, or a pharmaceutically acceptable salts, hydrate, or solvate thereof, 
     
     
         3 . The method for treating or preventing urinary incontinence according to  claim 1 , wherein the urinary incontinence is overactive bladder syndrome 
     
     
         4 . The method for treating or preventing urinary incontinence according to  claim 2 , wherein the urinary incontinence is overactive bladder syndrome. 
     
     
         5 . The method for treating or preventing urinary incontinence according to  claim 1 , wherein the urinary incontinence is urgency. 
     
     
         6 . The method for treating or preventing urinary incontinence according to  claim 1 , wherein the urinary incontinence is urge urinary incontinence. 
     
     
         7 . The method for treating or preventing urinary incontinence according to  claim 1 , wherein the urinary incontinence is stress urinary incontinence. 
     
     
         8 . The method for treating or preventing urinary incontinence according to  claim 1 , wherein the urinary incontinence is mixed urinary incontinence. 
     
     
         9 . The method for treating or preventing urinary incontinence according to  claim 2 , wherein the active ingredient 2 is an antimuscarinic agent 2a, vasopressin agonist 2b, Serotonin/Noradrenaline modulator 2c, or B3 agonist 2d 
     
     
         10 . The method for treating or preventing urinary incontinence according to  claim 9 , wherein the active ingredient 2 is an antimuscarinic agent 2a 
     
     
         11 . The method for treating or preventing urinary incontinence according to  claim 10 , wherein the antimuscarinic agent 2a is Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin, or Trospium, or a pharmaceutically acceptable acid addition salts, hydrates or solvate thereof. 
     
     
         12 . The method for treating or preventing urinary incontinence according to  claim 9 , wherein the active ingredient 2 is a vasopressin agonist 2b. 
     
     
         13 . The method for treating or preventing urinary incontinence according to  claim 12 , wherein the vasopressin agonists 2b is desmopressin, a pharmaceutically acceptable acid addition salt, hydrate, and/or solvate thereof. 
     
     
         14 . The method for treating or preventing urinary incontinence according to  claim 9 , wherein the active ingredient 2 is a Serotonin/Noradrenaline modulator 2c. 
     
     
         15 . The method for treating or preventing urinary incontinence according to  claim 14 , wherein the Serotonin/Noradrenaline modulator 2c is Venlafaxine, Duloxetine, Reboxetine, or Cizoliritine, or a pharmaceutically acceptable acid addition salts, hydrate, or solvate thereof. 
     
     
         16 . The method for treating or preventing urinary incontinence according to  claim 9 , wherein the active ingredient 2 is a β3 agonist 2d. 
     
     
         17 . The method for treating or preventing urinary incontinence according to  claim 16 , wherein the β3 agonist 2d is AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A, or CGP-12177A, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof. 
     
     
         18 . A pharmaceutical composition comprising a effective amount of Flibanserin 1 as one active ingredient in combination with and a therapeutically effective amount of an active ingredient 2. 
     
     
         19 . The pharmaceutical composition according to  claim 18 , wherein the active ingredient 2 is an antimuscarinic agent 2a, vasopressin agonist 2b, Serotonin/Noradrenaline modulator 2c, or B3 agonist 2d. 
     
     
         20 . The pharmaceutical composition according to  claim 19 , wherein the active ingredient 2 is an antimuscarinic agent 2a. 
     
     
         21 . The pharmaceutical composition according to  claim 20 , wherein the antimuscarinic agent 2a is Tolterodine, Oxybutynin, Darifenacin, Propiverine, Solifenacin, or Trospium, or a pharmaceutically acceptable acid addition salts, hydrate, or solvate thereof. 
     
     
         22 . The pharmaceutical composition according to  claim 19 , wherein the active ingredient 2 is a vasopressin agonist 2b. 
     
     
         23 . The pharmaceutical composition according to  claim 22 , wherein the vasopressin agonists 2b is desmopressin, or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof. 
     
     
         24 . The pharmaceutical composition according to  claim 19 , wherein the active ingredient 2 is one or more, preferably one Serotonin/Noradrenaline modulator 2c, optionally in combination with a pharmaceutically acceptable excipient. 
     
     
         25 . The pharmaceutical composition according to  claim 24 , wherein the Serotonin/Noradrenaline modulator 2c is Venlafaxine, Duloxetine, Reboxetine, or Cizoliritine, optionally in form of the or a pharmaceutically acceptable acid addition salt, hydrate, or solvate thereof. 
     
     
         26 . The pharmaceutical composition according to  claim 19 , wherein the active ingredient 2 is a β3 agonist 2d. 
     
     
         27 . The pharmaceutical composition according to  claim 26 , wherein the β3 agonist 2d is AD9677/TAK677, CL 316,243, SB 418790, L-796568, BMS-196085, BRL-35135A, CGP12177A, BTA-243, GW 427353, Trecanidine, Zeneca D7114, SR 59119, solabegron, CL616243, 2-[4-(2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl)phenoxy]-2-methylpropionic acid, BRL37344A or CGP-12177A, or a pharmaceutically acceptable acid addition salt, the hydrate, or solvate thereof. 
     
     
         28 .- 29 . (canceled)